{
    "nctId": "NCT06343948",
    "briefTitle": "A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer",
    "officialTitle": "A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer After Failure of at Least One Prior Line of Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "HR+HER2- Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 382,
    "primaryOutcomeMeasure": "Progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. No gender limit;\n3. Age \u226518 years old;\n4. expected survival time \u22653 months;\n5. Patients with unresectable locally advanced, recurrent metastatic HR+HER2- breast cancer;\n6. The subjects had received 1-2 lines of chemotherapy regimens in the unresectable locally advanced recurrence or metastasis stage, and had been treated with endocrine, CDK4/6 inhibitors, and taxanes;\n7. Documented radiographic disease progression;\n8. Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;\n9. Must have at least one measurable lesion according to RECIST v1.1 definition;\n10. ECOG score 0 or 1;\n11. Toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 defined by NCI-CTCAE v5.0;\n12. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n13. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before screening, and the organ function level must meet the requirements;\n14. Urine protein \u22642+ or \\< 1000mg/24h;\n15. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and it must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Prior receipt of an ADC drug with a topoisomerase I inhibitor as a toxin;\n2. Prior receipt of an ADC or antibody drug targeting EGFR and/or HER3;\n3. Chemotherapy, biological therapy, immunotherapy, etc., have been used within 4 weeks or 5 half-lives before the first dose, small molecule targeted therapy has been used within 5 days, palliative radiotherapy, modern Chinese medicine preparations approved by NMPA for anti-tumor therapy, etc., have been used within 2 weeks;\n4. anthracycline equivalent cumulative dose of adriamycin \\> 360 mg/m2;\n5. History of severe cardiovascular or cerebrovascular disease;\n6. Unstable deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening; Infusion-related thrombosis was excluded;\n7. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n8. Other malignant tumors diagnosed within 3 years before the first dose;\n9. Hypertension poorly controlled by two antihypertensive drugs; Patients with poor glycemic control;\n10. A history of interstitial lung disease (ILD) requiring steroid therapy, current ILD or grade \u22652 radiation pneumonitis, or suspicion of such disease on imaging during screening;\n11. Complicated pulmonary diseases leading to clinically severe respiratory function impairment;\n12. Patients with active central nervous system metastases;\n13. Patients with massive or symptomatic effusions or poorly controlled effusions;\n14. Imaging examination showed that the tumor had invaded or wrapped around the large blood vessels in the abdomen, chest, neck, and pharynx;\n15. Severe infection within 4 weeks before randomization; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;\n16. Was receiving \\&gt before randomization; Long-term systemic corticosteroid therapy with 10mg/ day prednisone or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy;\n17. Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;\n18. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n19. Patients with inflammatory bowel disease, extensive bowel resection history, immune enteritis history, intestinal obstruction or chronic diarrhea;\n20. Have a history of allergy to recombinant humanized antibodies or to BL-B01D1 and any excipients; A history of autologous or allogeneic stem cell transplantation;\n21. Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;\n22. A history of severe neurological or psychiatric illness;\n23. Received other unmarketed investigational drug or treatment within 4 weeks before the first dose; A live vaccine dose within 28 days before the planned dose or the first dose;\n24. Any complications or other circumstances deemed by the investigator to preclude participation in the trial.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}